308 related articles for article (PubMed ID: 20439985)
21. Comparative analysis of lysyl oxidase (like) family members in pulmonary fibrosis.
Aumiller V; Strobel B; Romeike M; Schuler M; Stierstorfer BE; Kreuz S
Sci Rep; 2017 Mar; 7(1):149. PubMed ID: 28273952
[TBL] [Abstract][Full Text] [Related]
22. Lysyl oxidase-like 2 (LOXL2)-mediated cross-linking of tropoelastin.
Schmelzer CEH; Heinz A; Troilo H; Lockhart-Cairns MP; Jowitt TA; Marchand MF; Bidault L; Bignon M; Hedtke T; Barret A; McConnell JC; Sherratt MJ; Germain S; Hulmes DJS; Baldock C; Muller L
FASEB J; 2019 Apr; 33(4):5468-5481. PubMed ID: 30676771
[TBL] [Abstract][Full Text] [Related]
23. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
[TBL] [Abstract][Full Text] [Related]
24. Lysyl oxidase like-2 contributes to renal fibrosis in Col4α3/Alport mice.
Cosgrove D; Dufek B; Meehan DT; Delimont D; Hartnett M; Samuelson G; Gratton MA; Phillips G; MacKenna DA; Bain G
Kidney Int; 2018 Aug; 94(2):303-314. PubMed ID: 29759420
[TBL] [Abstract][Full Text] [Related]
25. Lysyl Oxidase (LOX) Family Members: Rationale and Their Potential as Therapeutic Targets for Liver Fibrosis.
Chen W; Yang A; Jia J; Popov YV; Schuppan D; You H
Hepatology; 2020 Aug; 72(2):729-741. PubMed ID: 32176358
[TBL] [Abstract][Full Text] [Related]
26. Mass Spectrometry-Based Disulfide Mapping of Lysyl Oxidase-like 2.
Meier AA; Go EP; Moon HJ; Desaire H; Mure M
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682561
[TBL] [Abstract][Full Text] [Related]
27. Increased lysyl oxidase activity in aortas of hypertensive rats and effect of beta-aminopropionitrile.
Sheridan PJ; Kozar LG; Benson SC
Exp Mol Pathol; 1979 Apr; 30(2):315-24. PubMed ID: 33826
[No Abstract] [Full Text] [Related]
28. 2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.
Smithen DA; Leung LMH; Challinor M; Lawrence R; Tang H; Niculescu-Duvaz D; Pearce SP; Mcleary R; Lopes F; Aljarah M; Brown M; Johnson L; Thomson G; Marais R; Springer C
J Med Chem; 2020 Mar; 63(5):2308-2324. PubMed ID: 31430136
[TBL] [Abstract][Full Text] [Related]
29. A new role for LOX and LOXL2 proteins in transcription regulation.
Iturbide A; García de Herreros A; Peiró S
FEBS J; 2015 May; 282(9):1768-73. PubMed ID: 25103872
[TBL] [Abstract][Full Text] [Related]
30. Cloning and characterization of a fifth human lysyl oxidase isoenzyme: the third member of the lysyl oxidase-related subfamily with four scavenger receptor cysteine-rich domains.
Mäki JM; Tikkanen H; Kivirikko KI
Matrix Biol; 2001 Nov; 20(7):493-6. PubMed ID: 11691589
[TBL] [Abstract][Full Text] [Related]
31. Evolving roles of lysyl oxidase family in tumorigenesis and cancer therapy.
Ye M; Song Y; Pan S; Chu M; Wang ZW; Zhu X
Pharmacol Ther; 2020 Nov; 215():107633. PubMed ID: 32693113
[TBL] [Abstract][Full Text] [Related]
32. LOXL1 deficiency in the lamina cribrosa as candidate susceptibility factor for a pseudoexfoliation-specific risk of glaucoma.
Schlötzer-Schrehardt U; Hammer CM; Krysta AW; Hofmann-Rummelt C; Pasutto F; Sasaki T; Kruse FE; Zenkel M
Ophthalmology; 2012 Sep; 119(9):1832-43. PubMed ID: 22633114
[TBL] [Abstract][Full Text] [Related]
33. Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2).
Rowbottom MW; Bain G; Calderon I; Lasof T; Lonergan D; Lai A; Huang F; Darlington J; Prodanovich P; Santini AM; King CD; Goulet L; Shannon KE; Ma GL; Nguyen K; MacKenna DA; Evans JF; Hutchinson JH
J Med Chem; 2017 May; 60(10):4403-4423. PubMed ID: 28471663
[TBL] [Abstract][Full Text] [Related]
34. Knock-Out of the Five Lysyl-Oxidase Family Genes Enables Identification of Lysyl-Oxidase Pro-Enzyme Regulated Genes.
Liburkin-Dan T; Nir-Zvi I; Razon H; Kessler O; Neufeld G
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232621
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of lysyl oxidase‑like 2 ameliorates folic acid‑induced renal tubulointerstitial fibrosis.
Choi SE; Jeon N; Choi HY; Jeong HJ; Lim BJ
Exp Ther Med; 2022 Nov; 24(5):648. PubMed ID: 36168418
[TBL] [Abstract][Full Text] [Related]
36.
Yang YL; Tsai MC; Chang YH; Wang CC; Chu PY; Lin HY; Huang YH
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34206143
[TBL] [Abstract][Full Text] [Related]
37. Human lysyl oxidase-like 2.
Moon HJ; Finney J; Ronnebaum T; Mure M
Bioorg Chem; 2014 Dec; 57():231-241. PubMed ID: 25146937
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of (+)-catechin action on lysyl oxidase activity in aortic tissue.
DiSilvestro RA; Harris ED
Biochem Pharmacol; 1983 Jan; 32(2):343-6. PubMed ID: 6135426
[TBL] [Abstract][Full Text] [Related]
39. The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis.
Schilter H; Findlay AD; Perryman L; Yow TT; Moses J; Zahoor A; Turner CI; Deodhar M; Foot JS; Zhou W; Greco A; Joshi A; Rayner B; Townsend S; Buson A; Jarolimek W
J Cell Mol Med; 2019 Mar; 23(3):1759-1770. PubMed ID: 30536539
[TBL] [Abstract][Full Text] [Related]
40. SPECT Imaging of Lysyl Oxidase-like 2 in a Model of Idiopathic Pulmonary Fibrosis.
Vizier R; Garnier AR; Dias A; Moreau M; Claron M; Collin B; Denat F; Bellaye PS; Goncalves V
Mol Pharm; 2023 Jul; 20(7):3613-3622. PubMed ID: 37307296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
